Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its price objective raised by Wells Fargo & Company from $630.00 to ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

TNYA Stock Performance and Moving Averages. In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -12.95% over the last five trades ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...